Lal Alysandra, Chen Herbert
Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, H4/750 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA.
Ann Surg Oncol. 2007 Aug;14(8):2363-6. doi: 10.1245/s10434-007-9451-3. Epub 2007 May 24.
Tc-99-sestamibi scanning is utilized to determine whether patients with primary hyperparathyroidism (HPT) are candidates for minimally invasive parathyroidectomy (MIP). However, if the result of this scan is negative, many surgeons recommend bilateral parathyroid exploration because of possible multi-gland disease. The objectives of this study were to determine whether patients with primary HPT and negative sestamibi scans can benefit from additional imaging studies and are still potential candidates for MIP.
Between March 2001 and April 2006, 578 consecutive patients with HPT underwent parathyroidectomy by a single surgeon. Pre-operative sestamibi scans had been done in 458 (79%) of these patients, 90 (20%) of which had negative results. These patients formed our study cohort.
Of the 90 patients, 60 (67%) had a single adenoma, 17 (19%) double adenomas and 13 (14%) 3- to 4-gland hyperplasias. In 74 (82%) patients, localization was further investigated with one or more studies including thallium subtraction scans (n = 30), ultrasound (n = 15) and intra-operative internal jugular venous sampling (n = 49). Additionally, the use of radio-guided techniques intra-operatively facilitated minimally invasive techniques. Of these 90 patients, 47 had positive results from preoperative studies, including 12 positive thallium, 5 positive ultrasound and 13 positive internal jugular sampling results. In addition, positive results were observed for 17 patients using radio-probe techniques in the operating room. Accordingly, minimally invasive techniques were attempted in these 47 patients; 42 (89%) had single adenomas and in 5 the technique was converted to bilateral exploration for double adenoma/hyperplasia. In the setting of a negative sestamibi, the sensitivities of thallium scans and ultrasound were 30% and 27%, respectively. The overall cure rate in the 90 patients with negative sestamibi scans was 99%.
In patients with primary HPT and a negative sestamibi scan, most patients (67%) will have a single adenoma. These patients benefitted from additional localization tests, which yielded a positive result in 52% of patients. Therefore, even in the setting of a negative sestamibi scan, the majority of patients with primary HPT are still candidates for MIP.
利用锝-99-甲氧基异丁基异腈扫描来确定原发性甲状旁腺功能亢进症(HPT)患者是否适合进行微创甲状旁腺切除术(MIP)。然而,如果该扫描结果为阴性,许多外科医生会建议进行双侧甲状旁腺探查,因为可能存在多腺体疾病。本研究的目的是确定原发性HPT且甲氧基异丁基异腈扫描结果为阴性的患者是否能从额外的影像学检查中获益,以及是否仍是MIP的潜在候选者。
在2001年3月至2006年4月期间,578例连续的HPT患者由同一位外科医生进行了甲状旁腺切除术。其中458例(79%)患者术前行甲氧基异丁基异腈扫描,90例(20%)结果为阴性。这些患者构成了我们的研究队列。
在这90例患者中,60例(67%)为单发腺瘤,17例(19%)为双发腺瘤,13例(14%)为3至4腺体增生。在74例(82%)患者中,通过一项或多项检查进一步进行定位,包括铊减影扫描(n = 30)、超声(n = 15)和术中颈内静脉采血(n = 49)。此外,术中使用放射性引导技术有助于微创技术的实施。在这90例患者中,47例术前检查结果为阳性,包括12例铊扫描阳性、5例超声阳性和13例颈内静脉采血阳性。另外,17例患者在手术室使用放射性探头技术时结果为阳性。因此,对这47例患者尝试了微创技术;42例(89%)为单发腺瘤,5例因双发腺瘤/增生而将手术方式转为双侧探查。在甲氧基异丁基异腈扫描阴性的情况下,铊扫描和超声的敏感性分别为30%和27%。90例甲氧基异丁基异腈扫描阴性患者的总体治愈率为99%。
在原发性HPT且甲氧基异丁基异腈扫描阴性的患者中,大多数患者(67%)为单发腺瘤。这些患者从额外的定位检查中获益,52%的患者检查结果为阳性。因此,即使在甲氧基异丁基异腈扫描阴性的情况下,大多数原发性HPT患者仍是MIP的候选者。